Fort Lauderdale, Florida — Lurex Bio announced the formation of its Scientific Advisory Board (SAB), assembling a group of internationally recognized leaders in immunology, oncology, and translational medicine to guide the company’s next phase of platform development.
Lurex Bio is focused on developing non-viral, non-genetic immune engineering technologies designed to address a fundamental limitation in many current therapies: immune evasion rather than immune weakness. In numerous diseases, including cancer, abnormal cells persist not because the immune system cannot act, but because the signals required for recognition and response are absent, distorted, or actively suppressed.
“Many of today’s therapies rely on increasing immune force,” said Dr. Fred McCall-Perez, Chief Executive Officer of Lurex Bio. “Our approach is fundamentally different. The approach augments the cell surface by substituting immune-invisible features with a known, recognizable immune signal—enabling the immune system to identify otherwise latent cancer cells and resolve them through its natural, targeted response.”
Precision Over Force
While immunotherapy has transformed treatment paradigms, durable responses remain elusive for many patients. Increasingly, the challenge lies not in stimulating immune activity broadly, but in restoring accurate immune recognition—allowing the immune system to distinguish true biological problems from background noise and respond appropriately.
Lurex Bio’s platform technologies are designed to introduce transient, controllable biological signals at the cellular interface. By avoiding permanent genetic modification, the company’s approach emphasizes precision, reversibility, and adaptability across a range of disease contexts.
“Our goal is to work with the immune system’s inherent logic,” Dr. McCall-Perez added. “Precision and control are essential if immune-based therapies are to scale responsibly.”
Scientific Governance as a Strategic Asset
The Scientific Advisory Board will provide active scientific oversight as Lurex Bio advances its research and development programs. Members bring experience spanning academic discovery, clinical translation, and regulatory-grade development, helping ensure that platform evolution remains scientifically rigorous and clinically relevant.
According to James Clark, founder of Lurex Bio, the board reflects a deliberate commitment to discipline and long-term responsibility.
“Complex biology demands clarity and restraint,” Clark said. “By assembling this level of scientific leadership early, we’re building a foundation for technologies that are precise, ethical, and grounded in biological reality.”
Looking Ahead
As immunotherapy continues to mature, the field is shifting away from generalized activation toward refined immune control. Lurex Bio’s strategy aligns with this evolution, focusing on restoring correct immune recognition rather than amplifying immune force.
With its Scientific Advisory Board now in place, the company is positioning itself to contribute meaningfully to how next-generation immune therapies are designed, evaluated, and responsibly translated into clinical practice.
More information about Lurex Bio and its Scientific Advisory Board can be found at www.lurexbio.com.
